Articles tagged "Immunosuppression"

2019 American Transplant Congress
Everolimus/Low Tacrolimus Exposure versus Sodium Mycophenolate/Standard Tacrolimus for the Elderly Kidney Transplant Recipient. A 4-y Follow-Up of the nEverOld Trial
E. David-Neto, F. Agena, F. J. Paula, N. Z. Galante, D. S. David, F. Ramos, A. K. Triboni, P. Romano, P. A. Ebner, V. Coelho, M. Altona, R. Falci, A. Piovesan, W. C. Nahas
Renal Transplantation Service, Hospital das Clínicas - University of São Paulo School of Medicine, Sao Paulo, Brazil
*Purpose: The standard immunosuppressive regimen used for younger patients may not be adequate for the elderly cohort.*Methods: The nEverOld is a prospective, single-center, randomized trial…
2019 American Transplant Congress
Early Rejection Outcomes with IL-2 vs. ATG Induction among Kidney Transplant Recipients Induction Differences with Early Steroid Withdrawal
C. Burelli, A. Szczepanik, K. Yadav, E. Sanchez, M. Debroy, V. Humphreville, J. Rabets, A. Padiyar, N. Sarabu, A. Jittirat, A. Palanisamy, K. Chavin
University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: Early steroid withdrawal in kidney transplant (Ktx) patients is controversial and has demonstrated an increased risk of acute rejection with similar long-term outcomes. Data…
2019 American Transplant Congress
Alemtuzumab versus Antithymocyte Globulin Induction Immunosuppression in Highly Sensitized Kidney Transplant Recipients
A. Brueckner¹, E. Yanqui¹, C. Truong¹, R. Baliga², L. Bowman¹
¹Tampa General Hospital, Tampa, FL, ²Florida Kidney Physicians, Tampa, FL
*Purpose: Lymphocyte depleting agents such as rabbit anti-thymocyte globulin (rATG) and alemtuzumab are used for induction in highly sensitized (PRA ≥30%) kidney transplant recipients (KTRs).…
2019 American Transplant Congress
Association of Histological Findings in Renal Graft Biopsy with Non-Adherence to Immunosuppressive Treatment
B. D. Cardoso¹, J. Montagner², K. Pegas³, R. Kist⁴, J. Neumann⁵, H. S. Pinheiro⁶, V. D. Garcia⁴, E. Keitel¹
¹Department of Nephrology and Kidney Transplantation/ Post Graduation Program in Pathology, Irmandade Santa Casa de Misericórdia/ Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil, ²Transplant Immunology Laboratory,, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, ³Department of Pathology, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, ⁴Department of Nephrology and Kidney Transplantation, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, ⁵Transplant Immunology Laboratory, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, ⁶Renal Transplant Unit, NIEPEN/NIDEAL (UFJF), Porto Alegre, Brazil
*Purpose: Non-adherence to immunosuppressive treatment after renal transplantation is a frequent issue, but the magnitude of its impact has been debated. It is unknown whether…
2019 American Transplant Congress
Donor Derived Neoplasia: Will It Be a Risk after Clinical Pig Organ Xenotransplantation?
A. Jagdale¹, H. Iwase¹, E. Klein², D. Cooper¹
¹Surgery, University of Alabama at Birmingham, Birmingham, AL, ²Surgery, University of Pittsburgh, Pittsburgh, PA
*Purpose: The survival of the nonhuman primates with life-supporting pig kidney grafts has increased substantially (to >1 year). As clinical pig organ xenotransplantation draws closer,…
2019 American Transplant Congress
Utilization of LCP-Tacrolimus (ENVARSUS XR) in Simultaneous Pancreas and Kidney (SPK) Transplant Recipients
J. Torabi, A. Campbell, E. Akalin, M. Ajaimy, Y. Azzi, C. Pynadath, L. Liriano-Ward, J. P. Rocca, J. A. Graham
Montefiore Medical Center, Bronx, NY
*Purpose: The use of extended release tacrolimus (LCPT) allows for slow release of drug and once-daily dosing in transplant recipients. The improved bioavailability and decreased…
2019 American Transplant Congress
Breaking Concepts: 10-year Follow-Up of the Everolimus versus Azathioprine Heart Transplant Multi-National Study
J. A. Kobashigawa¹, R. Starling², E. Passano¹, P. Bernhardt³, B. Azarbal¹, R. Cheng¹, F. Esmailian¹, K. Khush⁴, D. Mancini⁵, J. Patel¹, T. Sato¹, S. Varnous⁶
¹Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, ²Cleveland Clinic, Cleveland, OH, ³Novartis Pharmaceuticals, Basel, Switzerland, ⁴Stanford University, Palo Alto, CA, ⁵Mount Sinai, New York, NY, ⁶APHP, Pitié‐Salpétrière, Sorbonne University, Paris, France
*Purpose: This study is the 10-year follow-up of a randomized double-blind prospective trial that compared everolimus (1.5 mg or 3 mg) to azathioprine. In this…
2019 American Transplant Congress
What’s in a High Dose? An Analysis of Tacrolimus Pharmacokinetic Parameters in Rapid Metabolizers
P. West-Thielke¹, A. Maldonado², S. J. Patel³, D. R. Stevens³, U. Meier-Kriesche³, D. Brennan⁴
¹University of Illinois, Chicago, Chicago, IL, ²Vidant Medical Center, Greenville, NC, ³Veloxis Pharmaceuticals Inc., Cary, NC, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: CYP3A5*1 expressers exhibit differences in immediate-release tacrolimus (IR-Tac) PK and require higher doses of IR-Tac to maintain therapeutic trough concentrations. LCP-Tacrolimus (LCPT) demonstrates a…
2019 American Transplant Congress
Tocilizumab for Refractory Antibody-Mediated Rejection in Pediatric Kidney Transplantation
A. Dokras, C. Butler, Q. Zhang, E. Reed, R. Ettenger, P. Weng, M. Pearl
University of California, Los Angeles, Los Angeles, CA
*Purpose: IL-6 blockade may play a role in reducing human leukocyte antigen donor specific antibodies (HLA DSA) production and stabilizing allograft function. We aimed to…
2019 American Transplant Congress
Hephaistos Study Outcome on Renal Function after 12 Month Everolimus Plus Reduced Tacrolimus in De Novo Liver Transplant Recipients versus Standard Tacrolimus
F. Braun¹, P. Schemmer¹, H. Schlitt¹, A. Pascher¹, C. Klein¹, U. Neumann¹, I. Kroeger², P. Wimmer², B. Nashan¹
¹Study Group, Hephaistos, Germany, ²Novartis Pharma GmbH, Nuernberg, Germany
*Purpose: The HEPHAISTOS study was designed to compare efficacy and safety of earlyuse of everolimus [EVR] combined with reduced tacrolimus [rTAC] versus Standard tacrolimus [TAC-C)…